Estimating power with effect size versus slop differences: Both means and variance matter

Alzheimer's and Dementia

Volumn 7, Issue 2, 2011, Pages 247-249

  Schneider, Lon S ^a   Kennedy, Richard E ^b   Cutter, Gary R ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; PLACEBO;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; CEREBROSPINAL FLUID; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); EXTERNAL VALIDITY; GENOTYPE; LETTER; MILD COGNITIVE IMPAIRMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RATING SCALE; SAMPLE SIZE; STATISTICAL ANALYSIS;

EID: 79952711258     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2011.02.003     Document Type: Letter

References (4)

1. 1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement 2011;7:245-6.
2. Schneider LS, Sano M. Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement 2009;5:388-97.
3. Maitournam A, Simon R. On the efficiency of targeted clinical trials. Stat Med 2005;24:329-39. (Pubitemid 40227650)
4. 1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement 2010;6:367-77.